← Signals
Signal

Genentech: Personalized Medicine Is Moving From Possibility To Platform

At Genentech, a member of the Roche Group, I addressed 550 executives in San Francisco and challenged them to think beyond breakthrough science toward the broader reinvention made possible by exponential genomics.

signal2025-2026keynote-case-study

What Jim Carroll was exploring

Recorded 2026-09-16. At Genentech, a member of the Roche Group, I addressed 550 executives in San Francisco and challenged them to think beyond breakthrough science toward the broader reinvention made possible by exponential genomics.

Archive status

This record preserves a dated excerpt. A contemporary assessment has not been added because the complete historical text and independent current evidence have not yet been verified.

Original archive reference

Keynote Case Study: Genentech: Personalized Medicine Is Moving From Possibility To Platform. (2026-09-16)

Connected knowledge

Trends

Connected knowledge

Industries

Connected knowledge

Domains

Connected knowledge

Sources

CONNECTED KNOWLEDGE

Go deeper

From Jim's archive

Original Jim Carroll articles connected to this topic. Their dates and titles preserve the historical context.

Signal record · dates and editorial status
Publish Date2026-09-16
Updated Date2026-09-22
Observed Date2026-09-16
Strengthstrong

These are tracking dates and editorial classifications, not dates of historical predictions.